Relevant bibliographies by topics / Mood stabilizer

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Mood stabilizer'

Author: Grafiati
Published: 4 June 2021
Last updated: 10 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Mood stabilizer.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Mood stabilizer"

1

Gould, Todd D., Guang Chen, and Husseini K. Manji. "Mood stabilizer psychopharmacology." Clinical Neuroscience Research 2, no. 3-4 (December 2002): 193–212. http://dx.doi.org/10.1016/s1566-2772(02)00044-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Ghaemi, S. Nassir. "On defining ‘mood stabilizer’." Bipolar Disorders 3, no. 3 (June 2001): 154–58. http://dx.doi.org/10.1034/j.1399-5618.2001.030304.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Maidment, Ian D. "The Use of Topiramate in Mood Stabilization." Annals of Pharmacotherapy 36, no. 7-8 (July 2002): 1277–81. http://dx.doi.org/10.1345/aph.1a398.

Full text
Abstract:
OBJECTIVE: To review data on the effectiveness of topiramate as a mood stabilizer. DATA SOURCES: Clinical literature accessed through MEDLINE (1985–September 2001) and the manufacturer. Key search terms included topiramate, mania, mood stabilizer, and bipolar disorder. DATA SYNTHESIS: The traditional standard therapy for bipolar disorder has been lithium. Other mood stabilizers are increasingly being used to manage this complex disorder. Studies that used topiramate in bipolar disorders were evaluated. CONCLUSIONS: The present data from open trials suggest that topiramate may possibly possess antimanic properties. Controlled, double-blind studies are required to confirm this efficacy.
APA, Harvard, Vancouver, ISO, and other styles
4

Burghardt, Kyle, Kristen Ward, Elani Sanders, Bradley Howlett, Berhane Seyoum, and Zhengping Yi. "Atypical Antipsychotics and the Human Skeletal Muscle Lipidome." Metabolites 8, no. 4 (October 13, 2018): 64. http://dx.doi.org/10.3390/metabo8040064.

Full text
Abstract:
Atypical antipsychotics (AAPs) are a class of medications associated with significant metabolic side effects, including insulin resistance. The aim of this study was to analyze the skeletal muscle lipidome of patients on AAPs, compared to mood stabilizers, to further understand the molecular changes underlying AAP treatment and side effects. Bipolar patients on AAPs or mood stabilizers underwent a fasting muscle biopsy and assessment of insulin sensitivity. A lipidomic analysis of total fatty acids (TFAs), phosphatidylcholines (PCs) and ceramides (CERs) was performed on the muscle biopsies, then lipid species were compared between treatment groups, and correlation analyses were performed with insulin sensitivity. TFAs and PCs were decreased and CERs were increased in the AAP group relative to those in the mood stabilizer group (FDR q-value <0.05). A larger number of TFAs and PCs were positively correlated with insulin sensitivity in the AAP group compared to those in the mood stabilizer group. In contrast, a larger number of CERs were negatively correlated with insulin sensitivity in the AAP group compared to that in the mood stabilizer group. The findings here suggest that AAPs are associated with changes in the lipid profiles of human skeletal muscle when compared to mood stabilizers and that these changes correlate with insulin sensitivity.
APA, Harvard, Vancouver, ISO, and other styles
5

McKinney, Parish, Ryan Finkenbine, and C. Lindsay DeVane. "Alopecia and Mood Stabilizer Therapy." Annals of Clinical Psychiatry 8, no. 3 (September 1, 1996): 183–85. http://dx.doi.org/10.3109/10401239609147756.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

GOODWIN, GUY M., and GIN S. MALHI. "What is a mood stabilizer?" Psychological Medicine 37, no. 05 (December 13, 2006): 609. http://dx.doi.org/10.1017/s0033291706009305.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Tohen, M., T. Jacobs, V. Toma, J. Francis, F. Zhang, K. S. Gannon, T. M. Sanger, and A. Breier. "Is olanzapine a mood-stabilizer?" Schizophrenia Research 41, no. 1 (January 2000): 193–94. http://dx.doi.org/10.1016/s0920-9964(00)90774-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Maidment, Ian D. "Lamotrigine — An Effective Mood Stabilizer?" Annals of Pharmacotherapy 33, no. 7-8 (July 1999): 864–67. http://dx.doi.org/10.1345/aph.18388.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Letmaier, M., D. Schreinzer, R. Wolf, and S. Kasper. "Topiramate as a mood stabilizer." International Clinical Psychopharmacology 16, no. 5 (September 2001): 295–98. http://dx.doi.org/10.1097/00004850-200109000-00008.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Tohen, M. F., T. G. Jacobs, P. D. Feldman, V. Toma, B. J. Francis, F. Zhang, T. M. Sanger, and A. Breier. "275. Is olanzapine a mood-stabilizer?" Biological Psychiatry 47, no. 8 (April 2000): S83. http://dx.doi.org/10.1016/s0006-3223(00)00539-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Mood stabilizer"

1

Shiah, I.-Shin. "Neuroendocrine challenge studies of serotonin and GABA function in mania and in the mechanism of action of the mood stabilizer divalproex sodium." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1999. http://www.collectionscanada.ca/obj/s4/f2/dsk1/tape10/PQDD_0017/NQ46424.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Kale, Andrea, and Yuliya Kuchanskaya. "Adherence to Mood Stabilizers Using a Pharmacy Prescription Database Analysis: Assessment of the Relationship of Non-Adherence to Hospitalization Rates, Cost of Care, and Gender for Patients with Bipolar Type I Disorder." The University of Arizona, 2006. http://hdl.handle.net/10150/624605.

Full text
Abstract:
Class of 2009 Abstract
Objectives: This study utilized a prescription claims database to retrospectively assess the relationship between adherence rates with a mood stabilizer in bipolar type I patients for: gender, age, psychiatric hospitalization rates, cost of services, and concomitant psychotropic medications. Methods: Adult patients with bipolar type I disorder (N=149; F=92 and M=57) who received at least two prescriptions of a mood stabilizer (i.e., carbamazepine, lamotrigine, lithium, oxcarbazepine, and valproic acid) during a 3-month intake period were included. Adherence to the mood stabilizer was retrospectively analyzed using high: >75% (> 274 days) vs. low: < 75% (< 274 days) supply of a mood stabilizer during 12-months. Results: Only 35.6% of the patients (N=53) met the criteria for > 75% adherence and 11.4% (N=17) met the criteria for > 90% adherence. There was a trend toward women having more days supply of a mood stabilizer compared to men (p=0.08) and older patients having a higher adherence rate with a mood stabilizer (p=0.06). The high adherence group had greater prescription costs (p<0.001) and total cost per year (R2=0.34, p=0.064) and more concomitant medications (p=0.04) than the low adherence group. Overall, there were no significant differences between the high and low adherence groups for mean hospital days, inpatient costs, and total cost of care. Among those patients that were hospitalized there was a negative correlation between adherence and inpatient cost (R2=0.49, p=0.024). Conclusions: Our findings suggest that patients with bipolar type I disorder demonstrate poor medication adherence with a mood stabilizer and that adherence rates based on a prescription claims database using two adherence categories may not be a predictive factor for psychiatric hospitalizations or cost of care.
APA, Harvard, Vancouver, ISO, and other styles
3

Schulze, Thomas G., Martin Alda, Mazda Adli, Nirmala Akula, Raffaella Ardau, Elise T. Bui, Caterina Chillotti, et al. "The International Consortium on Lithium Genetics (ConLiGen): An Initiative by the NIMH and IGSLI to Study the Genetic Basis of Response to Lithium Treatment." Saechsische Landesbibliothek- Staats- und Universitaetsbibliothek Dresden, 2014. http://nbn-resolving.de/urn:nbn:de:bsz:14-qucosa-134635.

Full text
Abstract:
For more than half a decade, lithium has been successfully used to treat bipolar disorder. Worldwide, it is considered the first-line mood stabilizer. Apart from its proven antimanic and prophylactic effects, considerable evidence also suggests an antisuicidal effect in affective disorders. Lithium is also effectively used to augment antidepressant drugs in the treatment of refractory major depressive episodes and prevent relapses in recurrent unipolar depression. In contrast to many psychiatric drugs, lithium has outlasted various pharmacotherapeutic ‘fashions’, and remains an indispensable element in contemporary psychopharmacology. Nevertheless, data from pharmacogenetic studies of lithium are comparatively sparse, and these studies are generally characterized by small sample sizes and varying definitions of response. Here, we present an international effort to elucidate the genetic underpinnings of lithium response in bipolar disorder. Following an initiative by the International Group for the Study of Lithium-Treated Patients (www.IGSLI.org) and the Unit on the Genetic Basis of Mood and Anxiety Disorders at the National Institute of Mental Health,lithium researchers from around the world have formed the Consortium on Lithium Genetics (www.ConLiGen.org) to establish the largest sample to date for genome-wide studies of lithium response in bipolar disorder, currently comprising more than 1,200 patients characterized for response to lithium treatment. A stringent phenotype definition of response is one of the hallmarks of this collaboration. ConLiGen invites all lithium researchers to join its efforts
Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich
APA, Harvard, Vancouver, ISO, and other styles
4

Pilhatsch, Maximilian, Tasha Glenn, Natalie Rasgon, Martin Alda, Kemal Sagduyu, Paul Grof, Rodrigo Munoz, et al. "Regularity of self‑reported daily dosage of mood stabilizers and antipsychotics in patients with bipolar disorder." Saechsische Landesbibliothek- Staats- und Universitaetsbibliothek Dresden, 2018. http://nbn-resolving.de/urn:nbn:de:bsz:14-qucosa-235821.

Full text
Abstract:
Background Polypharmacy is often prescribed for bipolar disorder, yet medication non-adherence remains a serious problem. This study investigated the regularity in the daily dosage taken of mood stabilizers and second generation antipsychotics. Methods Daily self-reported data on medications taken and mood were available from 241 patients with a diagnosis of bipolar disorder who received treatment as usual. Patients who took the same mood stabilizer or second generation antipsychotic for ≥ 100 days were included. Approximate entropy was used to determine serial regularity in daily dosage taken. Generalized estimating equations were used to estimate if demographic or clinical variables were associated with regularity. Results There were 422 analysis periods available from the 241 patients. Patients took drugs on 84.4% of days. Considerable irregularity was found, mostly due to single-day omissions and dosage changes. Drug holidays (missing 3 or more consecutive days) were found in 35.8% of the analysis periods. Irregularity was associated with an increasing total number of psychotropic drugs taken (p = 0.009), the pill burden (p = 0.026), and the percent of days depressed (p = 0.049). Conclusion Despite low missing percent of days, daily drug dosage may be irregular primarily due to single day omissions and dosage changes. Drug holidays are common. Physicians should expect to see partial adherence in clinical practice, especially with complex drug regimens. Daily dosage irregularity may impact the continuity of drug action, contribute to individual variation in treatment response, and needs further study.
APA, Harvard, Vancouver, ISO, and other styles
5

Schulze, Thomas G., Martin Alda, Mazda Adli, Nirmala Akula, Raffaella Ardau, Elise T. Bui, Caterina Chillotti, et al. "The International Consortium on Lithium Genetics (ConLiGen): An Initiative by the NIMH and IGSLI to Study the Genetic Basis of Response to Lithium Treatment." Karger, 2010. https://tud.qucosa.de/id/qucosa%3A27583.

Full text
Abstract:
For more than half a decade, lithium has been successfully used to treat bipolar disorder. Worldwide, it is considered the first-line mood stabilizer. Apart from its proven antimanic and prophylactic effects, considerable evidence also suggests an antisuicidal effect in affective disorders. Lithium is also effectively used to augment antidepressant drugs in the treatment of refractory major depressive episodes and prevent relapses in recurrent unipolar depression. In contrast to many psychiatric drugs, lithium has outlasted various pharmacotherapeutic ‘fashions’, and remains an indispensable element in contemporary psychopharmacology. Nevertheless, data from pharmacogenetic studies of lithium are comparatively sparse, and these studies are generally characterized by small sample sizes and varying definitions of response. Here, we present an international effort to elucidate the genetic underpinnings of lithium response in bipolar disorder. Following an initiative by the International Group for the Study of Lithium-Treated Patients (www.IGSLI.org) and the Unit on the Genetic Basis of Mood and Anxiety Disorders at the National Institute of Mental Health,lithium researchers from around the world have formed the Consortium on Lithium Genetics (www.ConLiGen.org) to establish the largest sample to date for genome-wide studies of lithium response in bipolar disorder, currently comprising more than 1,200 patients characterized for response to lithium treatment. A stringent phenotype definition of response is one of the hallmarks of this collaboration. ConLiGen invites all lithium researchers to join its efforts.
Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich.
APA, Harvard, Vancouver, ISO, and other styles
6

Jing, Yonghua. "Health Outcomes Assessment for Children and Adolescents with Bipolar Disorder Treated with and without Atypical Antipsychotics." University of Cincinnati / OhioLINK, 2009. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1235785106.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Takahashi, Tatsuichiro. "Factors associated with high-dose antipsychotic prescriptions in outpatients with schizophrenia: An analysis of claims data from a Japanese prefecture." Doctoral thesis, Kyoto University, 2021. http://hdl.handle.net/2433/265180.

Full text
Abstract:
京都大学
新制・課程博士
博士(医学)
甲第23408号
医博第4753号
新制||医||1052(附属図書館)
京都大学大学院医学研究科医学専攻
(主査)教授 中山 健夫, 教授 古川 壽亮, 教授 村井 俊哉
学位規則第4条第1項該当
Doctor of Medical Science
Kyoto University
DFAM
APA, Harvard, Vancouver, ISO, and other styles
8

Bartsch, Stefanie. "Auswirkung von Stimmungsstabilisierern und Antiepileptika auf die Zytokinproduktion in-vitro." Doctoral thesis, Universitätsbibliothek Leipzig, 2014. http://nbn-resolving.de/urn:nbn:de:bsz:15-qucosa-156211.

Full text
Abstract:
Die Bedeutung des Immunsystems in der Pathophysiologie von bipolaren Erkrankungen und Epilepsie ist ein aktueller Gegenstand der neuropsychoimmunologischen Forschung. Eine erhöhte Produktion von Zytokinen aufgrund von oxidativem Stress wurde dabei wiederholt als für die Pathophysiologie von Epilepsie und Bipolarer Störung relevant angesehen. In Hinblick auf Veränderungen der Zytokine Interleukin (IL)-1ß, IL-2, IL-4, IL-6 und Tumornekrosefaktor-alpha (TNF-α) wurden z. T. überlappende Ergebnisse bei beiden Erkrankungen beschrieben. Inwiefern diese Zytokine durch Stimmungsstabilisierer und Antiepileptika beeinflusst werden, wurde bisher jedoch nicht systematisch untersucht. In dieser Studie wurden systematisch in-vitro die Konzentrationen von IL-1ß, IL-2, IL-4, IL-6, IL-17, IL-22 und TNF-α im stimulierten Blut 14 gesunder Frauen mittels Vollblutverfahren (whole blood assay) nach Zugabe von Stimmungsstabilisierern bzw. Antiepileptika gemessen. Es wurden dabei die Stimmungsstabilisierer bzw. Antiepileptika Primidon, Carbamazepin, Levetiracetam, Lamotrigin, Valproat, Oxcarbazepin, Topiramat, Phenobarbital und Lithium untersucht. Die Ergebnisse lassen darauf schließen, dass der Mechanismus von erwünschter und unerwünschter anderer Wirkung von Stimmungsstabilisierern und Antiepileptika mit der Regulation von IL-1ß, IL-2, IL-22 und TNF-α in Zusammenhang stehen könnte. Getrennt nach den im Vollblutverfahren verwendeten Stimulanzien – Toxic-Shock-Syndrome-Toxin-1 (TSST-1) vs. monoklonaler Antikörper gegen das CD3-Oberflächenantigen (OKT3) in Kombination mit dem 5C3-Antikörper gegen CD40 (OKT3/CD40) – wurden die Ergebnisse in zwei unterschiedlichen Publikationen berichtet, die dieser Promotion zugrunde liegen.
APA, Harvard, Vancouver, ISO, and other styles
9

Shansis, Flavio Milman. "Escalas de avaliação do estado maníaco e de depressão : concordância na resposta a medicações estabilizadoras do humor em pacientes bipolares com sintomatologia mista." reponame:Biblioteca Digital de Teses e Dissertações da UFRGS, 2015. http://hdl.handle.net/10183/127226.

Full text
Abstract:
Introdução: Comparados com pacientes bipolares com episódios maníacos/hipomaníacos e depressivos, os que apresentam estados mistos tendem a curso mais grave da doença, início mais precoce, ocorrência mais frequente de sintomas psicóticos, maior risco de suicídio, altas taxas de comorbidade e tempo maior para remissão. Portanto, medidas objetivas de avaliação desses estados são necessárias. Objetivo:Avaliar a concordância entre três pares formados por uma de três escalas de mania (Young Mania Rating Scale (YMRS), Bech-Rafaelsen Mania Scale (BRMS) ou Clinician-Administered Rating Scale for Mania (CARS-M)) e uma de depressão (21-item Hamilton Depression) na avaliação da resposta a estabilizadores do humor em pacientes mistos. Método:Sessenta e oito (n=68) consecutivos pacientes ambulatoriais bipolares Tipo I e II com sintomatologia mista pelo DSM-IV-TR e pelos critérios de Cincinatti foram incluídos nesse estudo aberto de 8 semanas entre 2010 e 2014 foram randomizados para receberem em monoterapia, ácido valproico, carbamazepina ou carbonato de lítio. Resultados: O padrão de resposta (diminuição de, pelo menos, 50% em uma das escalas de mania e na de depressão) foi muito semelhante: 21-HAM-D + YMRS = 22,1%, 21-HAM-D + BRMS = 20,6% e 21-HAM-D + CARS-M = 23,5%; p < 0,368). Os resultados referentes à concordância de resposta revelam valores de kappa bastante altos: 21-HAM-D + YMRS X 21-HAM-D + CARS-M , Kappa = 0,87; 21-HAM-D + YMRS X 21-HAM-D + BRMS, Kappa = 0,78 e 21-HAM-D + CARS-M X 21-HAM-D + BRMS, Kappa = 0,91 (p < 0,001). Conclusões:O presente estudo sugere que qualquer uma das três escalas de mania utilizadas (YMRS, BRMS, CARS-M) pode ser associada à 21-HAM-D na avaliação da resposta em bipolares mistos.
Background: Compared with patients with bipolar disorder who exhibit pure manic/hypomanic or depressive episodes, the presence of mixed mood states is associated with a more severe course of illness, younger age of onset, more frequent ocurrence of psychotic symptoms, major risk of suicide, higher rates of comorbidities and longer time to achieve remission. Therefore, objective avaliation of these states are necessary. Objective: To evaluate the concorccance amog three pairs of three scales (Young Mania Rating Scale (YMRS), Bech-Rafaelsen Mania Scale (BRMS) or Clinician-Administered Rating Scale for Mania (CARS-M)) and a depression scale (21-item Hamilton Depression) in the assessment of response to humor stabizator drugs in mix bipolar patients. Methods: Sixty eight (n=68) consecutive bipolar type I and II outpatients with mixed sitomatology accordint to DSM-IV-TR and Cincinatti Criteria were included in these 8 weeks open-trial, from 2010 through 2014, to, randomly, receive monotherapy valporic acid, carbamazepine or lithium carbonate. Results: The response answer (decrease of, at least 50 %, in one of the mania and depression scales) were very similar: 21-HAM-D + YMRS = 22.1%, 21-HAM-D + BRMS = 20.6% e 21-HAM-D + CARS-M = 23.5%; p < 0,368). The kappa values were : 21-HAM-D + YMRS X 21-HAM-D + CARS-M , Kappa = 0.87; 21-HAM-D + YMRS X 21-HAM-D + BRMS, Kappa = 0.78 e 21-HAM-D + CARS-M X 21-HAM-D + BRMS, Kappa = 0.91 (p < 0,001). Conclusions: The present study suggests that any of the three mania scales used (YMRS, BRMS, CARS-M) may be associated to 21-HAM-D in the assessment of the response o bipolar patients.
APA, Harvard, Vancouver, ISO, and other styles
10

Piva, Roger Honorato. "Zircônia CO-dopada por compensação de cargas nos sistemas (ZrO2)1-(x+y)(InO1,5)x(MOz)y com MOz = TaO2,5, NbO2,5, MoO3 ou WO3, como revestimento para barreira térmica." Universidade Federal de São Carlos, 2016. https://repositorio.ufscar.br/handle/ufscar/8318.

Full text
Abstract:
Submitted by Alison Vanceto (alison-vanceto@hotmail.com) on 2016-10-25T10:51:21Z No. of bitstreams: 1 TeseRHP.pdf: 8778601 bytes, checksum: eb4553a13387041c0fd36d153b524c3c (MD5)
Approved for entry into archive by Marina Freitas (marinapf@ufscar.br) on 2016-11-08T19:10:09Z (GMT) No. of bitstreams: 1 TeseRHP.pdf: 8778601 bytes, checksum: eb4553a13387041c0fd36d153b524c3c (MD5)
Approved for entry into archive by Marina Freitas (marinapf@ufscar.br) on 2016-11-08T19:10:15Z (GMT) No. of bitstreams: 1 TeseRHP.pdf: 8778601 bytes, checksum: eb4553a13387041c0fd36d153b524c3c (MD5)
Made available in DSpace on 2016-11-08T19:10:21Z (GMT). No. of bitstreams: 1 TeseRHP.pdf: 8778601 bytes, checksum: eb4553a13387041c0fd36d153b524c3c (MD5) Previous issue date: 2016-09-30
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
InO1.5-stabilized zirconia (InSZ) is a potential hot corrosion resistant thermal barrier coating (TBC). However, the thermal instability prevents real applications of InSZ-based TBC. This thesis investigates the hypothesis of co-doping using the charge compensation to improve the phase stability of InSZ. Four co-doping systems were synthesized by coprecipitation and studied: (ZrO2)1-(x+y)(InO1.5)x(MOz)y with MOz = TaO2.5, NbO2.5, MoO3, or WO3. After synthesis, 9 mol% of InO1.5 plus the charge-compensating oxides was sufficient to stabilize the tetragonal phase. Specific surface area up to 106.1 m2.g-1 and crystallite size ~11 nm were achieved using ethanol washing followed by azeotropic distillation as dehydration technique in the precipitates. In these powders, initial thermal stability analysis indicated instability of the tetragonal phase, with extension of the t→m transformation less detrimental in the InMoSZ system. Further increase in the concentration of InO1.5:MoO3 results in monophasic samples with retention of cubic phase in the InMoSZ. Cubic InMoSZ exhibited hardness and thermal expansion coefficient of 13.5% and 9% higher than those of InSZ, respectively. However, thermal treatments at T ≥ 1200 °C showed that the InMoSZ is also passive to destabilization of the high temperature cubic polymorph. Although the cubic InMoSZ was the most promising system found in this thesis, the stability results do not support its application as TBC for temperatures ≥ 1000 ºC. A deep evaluation of the phase transformations between 1000 to 1200 °C indicated that the instability of the proposed systems is due to a progressive c→t→m destabilization of the polymorphs. This c→t→m transformation is directly associated with the reduction of the InO1.5 stabilizer in solid solution by volatilization as In2O during heat treatment. At temperatures ≤ 800 ºC, the c→t phase transformation do not occurs, then, InSZ-based TBC is stable in these conditions.
A zircônia estabilizada com InO1,5 (InSZ) é um material com potencial aplicação como revestimentos para barreira térmica (TBC) resistentes à corrosão. Contudo, a instabilidade de fases impede aplicações industriais da InSZ. Esta tese investiga a ação da co-dopagem por compensação de cargas como uma estratégia para aumentar a estabilidade de fases da InSZ. Quatro sistemas de co-dopagem foram sintetizados por co-precipitação e estudados: (ZrO2)1-(x+y)(InO1,5)x(MOz)y com MOz = TaO2,5, NbO2,5, MoO3 ou WO3. Após a síntese, 9 %mol de InO1,5 somado a concentração de óxidos compensadores de carga foi suficiente para estabilização da fase tetragonal. Área superficial específica de até 106,1 m2.g‒1 e tamanho de cristalitos de ~11 nm foram obtidos utilizando a lavagem com etanol seguida por destilação azeotrópica como técnica de desidratação dos precipitados. Para estes pós, testes de estabilidade térmica indicaram instabilidade da fase tetragonal, com extensão de transformação t→m menos detrimental no sistema InMoSZ. Aumentando gradativamente a concentração de InO1,5-MoO3 na InMoSZ resulta em amostras monofásicas com retenção da fase cúbica. A InMoSZ cúbica exibiu dureza e coeficiente de expansão térmica até 13,5% e 9% superiores aos valores da InSZ, respectivamente. No entanto, tratamentos em temperaturas ≥ 1200 ºC indicaram que a InMoSZ é também suscetível a desestabilização da fase cúbica. Embora a InMoSZ cúbica tenha sido o sistema mais promissor obtido nesta tese, os resultados de estabilidade indicam que sua aplicação como TBC não é possível em temperaturas ≥ 1000 ºC. Uma avaliação detalhada das fases formadas após os tratamentos entre 1000 a 1200 ºC demonstrou que a instabilidade dos sistemas estudados é decorrente de uma transformação progressiva tipo c→t→m. A origem da transformação c→t→m é associada a redução da concentração do estabilizador InO1,5 em solução sólida por volatilização como In2O durante os testes de estabilidade térmica. Em temperaturas ≤ 800 ºC, a transformação c→m não ocorre, neste caso, TBCs baseadas em InSZ são estáveis termicamente para aplicações industriais.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Mood stabilizer"

1

Corson, Timothy William. Mood stabilizer effects on expression of signal transducer genes implicated in bipolar disorder. Ottawa: National Library of Canada, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Stahl, S. M. Mood stabilizers. Cambridge: Cambridge University Press, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

M, Stahl S., ed. Antipsychotics and mood stabilizers: Stahl's essential psychopharmacology, 3rd edition. Cambridge: Cambridge University Press, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

de Leon, Jose, ed. A Practitioner's Guide to Prescribing Antiepileptics and Mood Stabilizers for Adults with Intellectual Disabilities. Boston, MA: Springer US, 2012. http://dx.doi.org/10.1007/978-1-4614-2012-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

De Aquino, João Paulo, and Robert Beech. Mood Stabilizer Monotherapy versus Adjunctive Antidepressant for Bipolar Depression. Edited by Ish P. Bhalla, Rajesh R. Tampi, Vinod H. Srihari, and Michael E. Hochman. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190625085.003.0004.

Full text
Abstract:
This chapter provides a summary of a landmark study on bipolar disorder, which aims to address the following question: In patients with bipolar disorder receiving mood-stabilizing agents, does adjunctive antidepressant therapy reduce the symptoms of bipolar depression without increasing the risk for mania? Starting with that question, the chapter describes the basics of the study, including funding, study location, who was studied, how many patients, study design, study intervention, follow-up, endpoints and results, in addition criticisms and limitations. Subsequently, other relevant studies are briefly reviewed and their clinical implications are discussed. Finally, a relevant clinical exemplifies the application of the current evidence behind the clinical question addressed by the study.
APA, Harvard, Vancouver, ISO, and other styles
6

Kwan, Melodie. Effect of the mood stabilizer valproate on intracellular calcium homeostatis in bipolar I disorder. 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Goldberg, Pablo H., Prerna Martin, Carolina Biernacki, and Moira A. Rynn. Treatments for Pediatric Bipolar Disorder. Oxford University Press, 2015. http://dx.doi.org/10.1093/med:psych/9780199342211.003.0009.

Full text
Abstract:
The past two decades have seen significant advances in the development of evidence-based treatments for pediatric bipolar disorder. Practice guidelines recommend pharmacotherapy with mood stabilizers or second-generation antipsychotics (SGAs) as the first-line treatment. Lithium, risperidone, aripiprazole, quetiapine, and olanzapine are approved by the U.S. Food & Drug Administration for treating bipolar disorder in children and adolescents. The pharmacological literature suggests that SGAs are faster and more effective than mood stabilizers in treating acute manic or mixed episodes, but they have significant side effects and require careful monitoring. While mild to moderate bipolar disorder can be treated with monotherapy, combination pharmacotherapy with an SGA and a mood stabilizer is recommended for youth with severe bipolar disorder. A growing body of literature also suggests the efficacy of psychosocial interventions, with family psychoeducation and skills building as adjunct treatments to pharmacotherapy. More type 1 studies of pharmacotherapy and psychosocial treatments are needed.
APA, Harvard, Vancouver, ISO, and other styles
8

Cavanna, Andrea E. Phenytoin. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198791577.003.0010.

Full text
Abstract:
Phenytoin is a first-generation antiepileptic drug characterized by a good range of antiepileptic indications, with an acceptable interaction profile in polytherapy. The reasons for the decreased use of phenytoin in patients with epilepsy include its narrow therapeutic index and potential for long-term toxicity, as well as the development of other antiepileptic drugs throughout the second half of the twentieth century. Phenytoin has a good behavioural tolerability profile and a restricted range of psychiatric uses. Despite occasional reports of adverse behavioural effects (especially at higher doses), there is some weak evidence for its potential usefulness as mood stabilizer and in the pharmacological management of impulsive aggression.
APA, Harvard, Vancouver, ISO, and other styles
9

Tacchi, Mary Jane, and Jan Scott. 5. The evolution of treatments. Oxford University Press, 2017. http://dx.doi.org/10.1093/actrade/9780199558650.003.0005.

Full text
Abstract:
For many centuries, the only intervention for melancholia involved admission into an asylum, initially to keep individuals away from society and then, from the 18th century, to provide therapeutic care. ‘The evolution of treatments’ discusses the crude treatments that were first introduced for inpatients such as sedation (barbiturates and insulin coma therapy) and physical treatments (electroconvulsive therapy and psychosurgery). Next, it discusses the development of the medications that are used today for inpatients and outpatients, such as antidepressants and the mood stabilizer lithium. Finally, it looks at the evolution of psychotherapies from early Freudian models through to mindfulness and the potential barriers to providing psychological interventions in the real world.
APA, Harvard, Vancouver, ISO, and other styles
10

Hazell, Philip. The treatment of bipolar disorder in children and adolescents. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198748625.003.0021.

Full text
Abstract:
The presentation of bipolar disorder in young people can be different from that of adults; therefore, the approach to treatment differs slightly. Treatment is described for early intervention, acute mania, bipolar depression, relapse prevention, and refractory bipolar disorder. A strong therapeutic alliance with the patient and engagement and involvement of the patient’s family is critical to successful intervention. The evidence informing treatment is limited, but there is emerging research focused on the management of acute mania favouring monotherapy with a second-generation antipsychotic (SGA) over a mood stabilizer. Preliminary data favour a combination of an SGA and antidepressant over monotherapy with an SGA for the treatment of bipolar depression. Guidelines endorse electroconvulsive therapy for refractory mania and bipolar depression but there is no clinical trial evidence to support this practice. The development of algorithms to guide the management of all phases of bipolar disorder is a work in progress.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Mood stabilizer"

1

Menke, Andreas. "Mood Stabilizer: Definition." In NeuroPsychopharmacotherapy, 1–2. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-319-56015-1_35-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Rybakowski, Janusz K. "Lithium as Mood Stabilizer." In Encyclopedia of Metalloproteins, 1208–13. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4614-1533-6_333.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Trenckmann, U., and B. Bandelow. "Rückfallvorbeugende Medikamente bei phasenhaft verlaufenden Gemütsleiden (sog. „Mood Stabilizer“)." In Psychiatrie und Psychotherapie, 115–18. Heidelberg: Steinkopff, 1999. http://dx.doi.org/10.1007/978-3-642-58700-9_26.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Muzina, David J., David E. Kemp, and Joseph R. Calabrese. "Mood Stabilizers." In Psychiatry, 2202–22. Chichester, UK: John Wiley & Sons, Ltd, 2008. http://dx.doi.org/10.1002/9780470515167.ch103.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Gerlach, Manfred, and Andreas Warnke. "Mood Stabilizers." In Psychiatric Drugs in Children and Adolescents, 257–91. Vienna: Springer Vienna, 2014. http://dx.doi.org/10.1007/978-3-7091-1501-5_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Morgan, Michael M., MacDonald J. Christie, Thomas Steckler, Ben J. Harrison, Christos Pantelis, Christof Baltes, Thomas Mueggler, et al. "Mood Stabilizers." In Encyclopedia of Psychopharmacology, 796–98. Berlin, Heidelberg: Springer Berlin Heidelberg, 2010. http://dx.doi.org/10.1007/978-3-540-68706-1_259.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Goodwin, Guy M. "Mood Stabilizers." In Encyclopedia of Psychopharmacology, 1–4. Berlin, Heidelberg: Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-642-27772-6_259-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Spina, Edoardo, and Domenico Italiano. "Mood Stabilizers." In Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents, 177–203. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-27883-4_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Sadek, Joseph. "Mood Stabilizers." In Clinician’s Guide to Psychopharmacology, 79–111. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-60766-1_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Behere, Prakash B., Anweshak Das, and Aniruddh P. Behere. "Mood Stabilizers." In Clinical Psychopharmacology, 99–116. Singapore: Springer Singapore, 2018. http://dx.doi.org/10.1007/978-981-13-2092-7_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Mood stabilizer"

1

Mahato, Ajay Kumar, and Anu Samanta. "Temperature stabilized CMOS ring oscillator." In 2013 IEEE International Conference in MOOC, Innovation and Technology in Education (MITE). IEEE, 2013. http://dx.doi.org/10.1109/mite.2013.6756333.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Augustin, M. "3 Therapeutic Drug Monitoring of antiepileptics and mood stabilizers in pregnancy and lactation." In XIVth Symposium of the Task Force Therapeutic Drug Monitoring of the AGNP. © Georg Thieme Verlag KG, 2020. http://dx.doi.org/10.1055/s-0040-1710111.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Solin, Jussi, Sven Reese, H. Ertugrul Karabaki, and Wolfgang Mayinger. "Environmental Fatigue Factors (NUREG/CR-6909) and Strain Controlled Data for Stabilized Austenitic Stainless Steel." In ASME 2013 Pressure Vessels and Piping Conference. American Society of Mechanical Engineers, 2013. http://dx.doi.org/10.1115/pvp2013-97500.

Full text
Abstract:
Experimental research on fatigue performance of niobium stabilized stainless steel (1.4550, X6CrNiNb1810 mod) relevant for German NPP primary piping has previously demonstrated good long life performance. Slow rate fatigue tests in 325 °C PWR water are first time presented and discussed in this paper. Good fatigue performance was measured also in hot water. Our experiments give consistently about doubled lives or 50% smaller Fen factors in compared to predictions by NUREG 6909. Transferability of the laboratory data, reference and design curves together with the proposed Fen evaluation procedure to component evaluation will be discussed.
APA, Harvard, Vancouver, ISO, and other styles
4

Kim, G. E., P. G. Tsantrizos, S. Grenier, A. Cavasin, and T. Brzezinski. "Near Net-Shape Forming of Thermal Barrier Coated Components for Gas Turbine Engine Applications." In ITSC 1998, edited by Christian Coddet. ASM International, 1998. http://dx.doi.org/10.31399/asm.cp.itsc1998p1229.

Full text
Abstract:
Abstract Many of the recent improvements in gas turbine engines have been attributed to the introduction of thermal barrier coatings (TBC) for superalloy components. There exists, however, some limitations in current fabrication methods for closed hot-section components: less than ideal coating quality, the need for welding, and limited choice of superalloy material. This paper describes a vacuum plasma near-net-shape process that overcomes these limitations. The process is used to fabricate closed components from yttria-stabilized-zirconia with a CoNiCrAlY bond coat and IN-738LC outer layer. The results from the study show that it is possible to produce near-net-shape superalloy parts with good coating properties and the absence of welds. The mold was reusable after minor reconditioning and the coatings were uniform in thickness and microstructure with a smooth surface finish. The bond coat and structural superalloy layers were very dense with no signs of oxidation at the interface. After heat treatment, the mechanical properties of the IN-738LC compare favorably to cast materials.
APA, Harvard, Vancouver, ISO, and other styles
5

Gitzhofer, F., K. Mailhot, M. I. Boulos, I. H. Jung, J. S. Lee, and H. S. Park. "Fabrication of Simulated Nuclear Fuel Pellets by Induction Plasma Deposition." In ITSC 1998, edited by Christian Coddet. ASM International, 1998. http://dx.doi.org/10.31399/asm.cp.itsc1998p1283.

Full text
Abstract:
Abstract A study on induction plasma shape forming with ceramic materials, yttria stabilized zirconia ZrO2-Y2O3 (YSZ), was conducted in order to develop a new method for nuclear fuel fabrication. YSZ was selected because of its similar melting point then U02. Nuclear fuel consists of pellets Ø 10mm, thickness 12mm with a density over 96% theoretical density (TD). Process optimization was done with two different approaches: A large induction plasma flame (70mm), high number of pellets simultaneously sprayed (up to 108 pellets) and a medium power (40-50 kW) small supersonic induction plasma flame (10mm) for 1 pellet fabrication at a time. Process optimization was intensively done for the large induction plasma flame using chamber pressure, plasma plate power, powder spraying distance, sheath gas composition, probe position and particle size. The best results were 97.11% TD for 5mm thick pellets and 94% TD with the multi-pellets mold wheel type. For the single pellet approach, density as high as 99% TD has been obtained as measured on 12mm thick free standing pellets.
APA, Harvard, Vancouver, ISO, and other styles
6

Solin, Jussi, Sven Reese, and Wolfgang Mayinger. "Fatigue Performance of Stainless Steel in NPP Service Conditions." In ASME 2012 Pressure Vessels and Piping Conference. American Society of Mechanical Engineers, 2012. http://dx.doi.org/10.1115/pvp2012-78721.

Full text
Abstract:
Fatigue of Niobium stabilized austenitic stainless steel (X6CrNiNb1810 mod) is studied using specimens extracted from a solution annealed and quenched primary piping material sample. This paper reports and discusses new results complementing the data published in PVP2009 and 2011, where good long life performance was demonstrated and relevance of the new design curve in ASME III was questioned. Effects of temperature and operational loading sequences are in focus here. A typical case with steady state operation between fatigue cycles was roughly simulated in periodically interrupted tests. An extension of fatigue life due to hardening during the holds in elevated temperature was demonstrated and here we show that the hardening effect is generic. It occurs also in isothermal conditions, where straining and holds are both at 325 °C, irrespective of the phase within a cycle, where the hold is introduced, and also for other austenitic steel grades. Fatigue assessment based on standard fatigue data seems to underestimate fatigue performance of materials subjected to typical thermal transients in nuclear piping during operation.
APA, Harvard, Vancouver, ISO, and other styles
7

Solin, Jussi, Sven Reese, and Wolfgang Mayinger. "Long Life Fatigue Performance of Stainless Steel." In ASME 2011 Pressure Vessels and Piping Conference. ASMEDC, 2011. http://dx.doi.org/10.1115/pvp2011-57942.

Full text
Abstract:
Fatigue of Niobium stabilized austenitic stainless steel (X6CrNiNb1810 mod) was studied using specimens extracted from a solution annealed and quenched primary piping material sample. This paper reports and discusses results of non-standard experiments to complement previously published test data. The NPP primary piping components spend long times in operation temperature between fatigue cycles originating from thermal transients. This was roughly simulated by fatigue tests periodically interrupted for intermediate annealing in elevated temperature. Fatigue endurance was notably increased when low strain amplitudes were used. The life extension is explained by the cyclic stress strain response. Hardening followed by slow cyclic softening was consistently observed after annealing. It is generally assumed that cumulative accumulation of fatigue damage occurs at a wide range of loading amplitudes. We performed two level and spectrum straining tests combining amplitudes above and below the (Nf &gt; 107) endurance limit. The endurance limit seems to be effective also in variable amplitude loading. In terms of modified Miner rule, even “negative damage” was obtained in two level tests below and above the constant amplitude endurance limit. This behavior is linked to prominent secondary hardening of the steel.
APA, Harvard, Vancouver, ISO, and other styles
8

Aguirre, Milton E., and Mary Frecker. "Design and Optimization of Hybrid Compliant Narrow-Gauge Surgical Forceps." In ASME 2010 Conference on Smart Materials, Adaptive Structures and Intelligent Systems. ASMEDC, 2010. http://dx.doi.org/10.1115/smasis2010-3732.

Full text
Abstract:
This work describes a design and optimization method for developing hybrid, multi-material, compliant instruments which are expected to be useful in mini-laparoscopy and natural orifice translumenal endoscopic surgery. These two-material devices are designed specifically for Penn State’s lost mold rapid infiltration process, which is capable of fabricating hundreds of freestanding meso-scale parts in parallel. New narrow-gauge surgical procedures impose severe geometric constraints that challenge traditional compliant mechanism design methods. Since narrow-gauge constraints leave geometry optimization ineffective, new design methods are explored to improve the performance of a 1 mm diameter contact-aided compliant forceps. By considering hybrid designs, new design possibilities are enabled through material variation. The hybrid forceps has desired regions of flexibility and stiffness that can be isolated to improve tool performance. For instance, a hybrid forceps can be designed with greater flexibility in some regions to provide larger jaw openings while maintaining high stiffness in other regions to obtain large grasping forces, both vital features in a surgical forceps. Using ANSYS to model large deformation and contact, an optimization problem is formulated to maximize tool performance and to determine optimal segregation of hybrid materials considering a range of modulus ratios. Materials under consideration include nanoparticulate 3 mol% yttria partially stabilized zirconia (3YSZ) and austenitic (300 series) stainless steel. All results are compared to previously optimized homogeneous designs.
APA, Harvard, Vancouver, ISO, and other styles
9

Leartcheongchowasak, Sornkrit, Merwan Mehta, Hamid Al-Kadi, Keith Sequeira, Brian Snow, Kenneth W. Ragsdell, and Louis Baja. "Robust Parameter Design of the Precision Injection Molding Process." In ASME 1994 Design Technical Conferences collocated with the ASME 1994 International Computers in Engineering Conference and Exhibition and the ASME 1994 8th Annual Database Symposium. American Society of Mechanical Engineers, 1994. http://dx.doi.org/10.1115/detc1994-0106.

Full text
Abstract:
Abstract The most important problem, causing defective parts, in the injection molding process, is nonuniform shrinkage of molded parts. This leads to an iterative trial-and-error cycles of modification of mold cavity and core to arrive at the right dimensional size required which can occasionally to complete retooling. For this process, there are many factors that can be thrown out of control. Using the traditional scientific approach, engineers have longed to understand the mechanics of the process to control it, with limited success. In this paper, a design of experiments setup, using the Taguchi Methods, was done to reduce the nonuniform shrinkage. The company where the experiment was carried out is a precision parts molder for their own product lines. By using the internal experts from the company, a list of independent process parameters with no interactions which were thought the most responsible for dimensional size were listed. As there were 13 such parameters, it was decided to use the L27 orthogonal array. The optimum value that the company experts thought would produce the right part were used as the settings for the initial experiment. The 27 experiments were then performed, allowing sufficient time to let the machine stabilized between the experiments. The S/N ratio calculation for 27 experiments was explained. Next the calculations for the percentage that each parameter contributes to the dimension was determined. Finally, a confirmation experiment was performed to verify the results.
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Mood stabilizer"

1

Viswanathan, Meera, Jennifer Cook Middleton, Alison Stuebe, Nancy Berkman, Alison N. Goulding, Skyler McLaurin-Jiang, Andrea B. Dotson, et al. Maternal, Fetal, and Child Outcomes of Mental Health Treatments in Women: A Systematic Review of Perinatal Pharmacologic Interventions. Agency for Healthcare Research and Quality (AHRQ), April 2021. http://dx.doi.org/10.23970/ahrqepccer236.

Full text
Abstract:
Background. Untreated maternal mental health disorders can have devastating sequelae for the mother and child. For women who are currently or planning to become pregnant or are breastfeeding, a critical question is whether the benefits of treating psychiatric illness with pharmacologic interventions outweigh the harms for mother and child. Methods. We conducted a systematic review to assess the benefits and harms of pharmacologic interventions compared with placebo, no treatment, or other pharmacologic interventions for pregnant and postpartum women with mental health disorders. We searched four databases and other sources for evidence available from inception through June 5, 2020 and surveilled the literature through March 2, 2021; dually screened the results; and analyzed eligible studies. We included studies of pregnant, postpartum, or reproductive-age women with a new or preexisting diagnosis of a mental health disorder treated with pharmacotherapy; we excluded psychotherapy. Eligible comparators included women with the disorder but no pharmacotherapy or women who discontinued the pharmacotherapy before pregnancy. Results. A total of 164 studies (168 articles) met eligibility criteria. Brexanolone for depression onset in the third trimester or in the postpartum period probably improves depressive symptoms at 30 days (least square mean difference in the Hamilton Rating Scale for Depression, -2.6; p=0.02; N=209) when compared with placebo. Sertraline for postpartum depression may improve response (calculated relative risk [RR], 2.24; 95% confidence interval [CI], 0.95 to 5.24; N=36), remission (calculated RR, 2.51; 95% CI, 0.94 to 6.70; N=36), and depressive symptoms (p-values ranging from 0.01 to 0.05) when compared with placebo. Discontinuing use of mood stabilizers during pregnancy may increase recurrence (adjusted hazard ratio [AHR], 2.2; 95% CI, 1.2 to 4.2; N=89) and reduce time to recurrence of mood disorders (2 vs. 28 weeks, AHR, 12.1; 95% CI, 1.6 to 91; N=26) for bipolar disorder when compared with continued use. Brexanolone for depression onset in the third trimester or in the postpartum period may increase the risk of sedation or somnolence, leading to dose interruption or reduction when compared with placebo (5% vs. 0%). More than 95 percent of studies reporting on harms were observational in design and unable to fully account for confounding. These studies suggested some associations between benzodiazepine exposure before conception and ectopic pregnancy; between specific antidepressants during pregnancy and adverse maternal outcomes such as postpartum hemorrhage, preeclampsia, and spontaneous abortion, and child outcomes such as respiratory issues, low Apgar scores, persistent pulmonary hypertension of the newborn, depression in children, and autism spectrum disorder; between quetiapine or olanzapine and gestational diabetes; and between benzodiazepine and neonatal intensive care admissions. Causality cannot be inferred from these studies. We found insufficient evidence on benefits and harms from comparative effectiveness studies, with one exception: one study suggested a higher risk of overall congenital anomalies (adjusted RR [ARR], 1.85; 95% CI, 1.23 to 2.78; N=2,608) and cardiac anomalies (ARR, 2.25; 95% CI, 1.17 to 4.34; N=2,608) for lithium compared with lamotrigine during first- trimester exposure. Conclusions. Few studies have been conducted in pregnant and postpartum women on the benefits of pharmacotherapy; many studies report on harms but are of low quality. The limited evidence available is consistent with some benefit, and some studies suggested increased adverse events. However, because these studies could not rule out underlying disease severity as the cause of the association, the causal link between the exposure and adverse events is unclear. Patients and clinicians need to make an informed, collaborative decision on treatment choices.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Mood stabilizer' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography